AI drug discovery research consortium adds six new members
OpenFold, a non-profit artificial intelligence (AI) research consortium focused on developing free and open-source software tools for biology and drug discovery, has added six new industry members.
Joining the consortium are Astex Pharmaceuticals, Biogen, Congruence Therapeutics, Polaris Quantum Biotech, Psivant Therapeutics, and SandboxAQ.
“This expansion marks a significant stride forward in advancing AI-driven solutions for healthcare and life sciences,” said Christina Taylor, Senior Science Fellow at Bayer Crop Science and executive member of OpenFold. “Our new members bring considerable expertise to our AI platform development programs.”
OpenFold, a consortium of academic and industry partners founded in February 2022, is a project of the Open Molecular Software Foundation, a non-profit organisation advancing molecular sciences by building communities for open-source research software development.
The new members join OpenFold’s founders and existing members: Mohammed AlQuraishi’s Laboratory, Arzeda, Basecamp Research, Bayer, CHARMM Therapeutics, Cyrus Biotechnology, Dassault Systemes, Gabriel Rocklin’s Laboratory, NVIDIA, Outpace, Puxano, UCB, and Valence Labs.
The new consortium members
Astex Pharmaceuticals of Cambridge, UK joins the consortium with a focus on structure-based drug design. A spokesperson commented: “Structure-based drug design is fundamental to our drug discovery strategy, and we are excited by the new generation of structure prediction tools. OpenFold’s work is crucial in bringing academia and industry together to push the performance and accuracy of these tools which aim to enable discovery and development of better medicines for patients.”
Congruence Therapeutics, headquartered in Bethesda, Maryland, advances treatments for neurodegenerative disorders. They said: “OpenFold is the gold standard of AI research consortiums, and we share their passion for engineering the medicines of the future.”
SandboxAQ, headquartered in Palo Alto, California, is keen to share expertise to advance healthcare outcomes. “SandboxAQ is proud to contribute its biopharma knowledge and Quantitative AI simulation expertise to support the OpenFold Consortium and advance software solutions that have real-world impact in healthcare and life sciences,” said Andrea Bortolato, Director of Drug Discovery at SandboxAQ.
Polaris Quantum Biotech (PolarisQB), headquartered in Durham, NC, built the Quantum-Aided Drug Design (QuADD) platform. “Polaris Quantum Biotech is thrilled to join OpenFold and its community of like-minded companies. We are especially excited to contribute to the development of open-source tools to expedite drug discovery,” said Dr Shahar Keinan, CEO of PolarisQB.
Dr Woody Sherman, Founder of Psivant Therapeutics of Boston, Massachusetts, added: “This collaboration enhances our ability to design better drugs using advanced computational tools. We believe a vibrant open science community is vital to the future of drug discovery.”
Diana Spencer, Senior Digital Content Editor, DDW
